Gorica Maric1, Tatjana Pekmezovic1, Sarlota Mesaros2,3, Olivera Tamas2,3, Nikola Veselinovic2,3, Maja Budimkic Stefanovic2,3, Aleksa Jovanovic1, Jelena Drulovic4,5. 1. Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 2. Clinic of Neurology, University Clinical Center of Serbia, Dr Subotica 6, 11000 Belgrade, Belgrade, Serbia. 3. Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 4. Clinic of Neurology, University Clinical Center of Serbia, Dr Subotica 6, 11000 Belgrade, Belgrade, Serbia. drulovicjelena@gmail.com. 5. Faculty of Medicine, University of Belgrade, Belgrade, Serbia. drulovicjelena@gmail.com.
Abstract
INTRODUCTION: Among different comorbidities occurring in multiple sclerosis (MS), the presence of malignant diseases in these patients is of the particular importance. The aim of this study was to determine the malignant diseases burden in a whole cohort of patients with MS in the Belgrade region, based on the Belgrade population registry data. MATERIAL AND METHODS: This study comprises 2725 MS patients from the MS Registry, which represents a source for all necessary demographic and clinical data. Firstly, the Registry was searched for all persons with MS who had cancer comorbidity, during the period 1996-2019. Diagnosis of cancer was validated by the patients' medical documentation. In order to investigate factors associated with the occurrence of any type of the cancer and/ or breast cancer only, in persons with MS, different logistic regression analyses were performed. RESULTS: A total of 64 persons with 69 malignant diseases were observed (prevalence 2.53%). The most frequent malignancies in males were skin cancer (50.0%) and in females, breast cancer (23.2%). The cumulative incidence of cancer comorbidity in persons with MS was 324.9 new cases per 100,000 person-years for the total population (137.6/100,000 in males and 403.6 per 100,000 in females). Comparison of cancer incidence rate between MS and general Belgrade population revealed lower risk for malignancy occurrence in the MS population in total (standardized incidence ratio, SIR = 0.58, 95% CI 0.16-1.49). CONCLUSIONS: Our findings demonstrate that MS patients in the Belgrade region have lower risk for the development of malignancy than age- and sex-matched general population.
INTRODUCTION: Among different comorbidities occurring in multiple sclerosis (MS), the presence of malignant diseases in these patients is of the particular importance. The aim of this study was to determine the malignant diseases burden in a whole cohort of patients with MS in the Belgrade region, based on the Belgrade population registry data. MATERIAL AND METHODS: This study comprises 2725 MS patients from the MS Registry, which represents a source for all necessary demographic and clinical data. Firstly, the Registry was searched for all persons with MS who had cancer comorbidity, during the period 1996-2019. Diagnosis of cancer was validated by the patients' medical documentation. In order to investigate factors associated with the occurrence of any type of the cancer and/ or breast cancer only, in persons with MS, different logistic regression analyses were performed. RESULTS: A total of 64 persons with 69 malignant diseases were observed (prevalence 2.53%). The most frequent malignancies in males were skin cancer (50.0%) and in females, breast cancer (23.2%). The cumulative incidence of cancer comorbidity in persons with MS was 324.9 new cases per 100,000 person-years for the total population (137.6/100,000 in males and 403.6 per 100,000 in females). Comparison of cancer incidence rate between MS and general Belgrade population revealed lower risk for malignancy occurrence in the MS population in total (standardized incidence ratio, SIR = 0.58, 95% CI 0.16-1.49). CONCLUSIONS: Our findings demonstrate that MS patients in the Belgrade region have lower risk for the development of malignancy than age- and sex-matched general population.
Authors: Jose M Valderas; Barbara Starfield; Bonnie Sibbald; Chris Salisbury; Martin Roland Journal: Ann Fam Med Date: 2009 Jul-Aug Impact factor: 5.166
Authors: A Lalmohamed; M T Bazelier; T P Van Staa; B M J Uitdehaag; H G M Leufkens; A De Boer; F De Vries Journal: Eur J Neurol Date: 2012-02-21 Impact factor: 6.089
Authors: Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; James Blanchard; Stella Leung; Nancy Yu Journal: Neurology Date: 2015-05-27 Impact factor: 9.910
Authors: Ruth Ann Marrie; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Per Soelberg Sørensen; Stephen Reingold; Gary Cutter; Nadia Reider Journal: Mult Scler Date: 2015-01-26 Impact factor: 6.312
Authors: Jeremy Hobart; Amy Bowen; George Pepper; Harriet Crofts; Lucy Eberhard; Thomas Berger; Alexey Boyko; Cavit Boz; Helmut Butzkueven; Elisabeth Gulowsen Celius; Jelena Drulovic; José Flores; Dana Horáková; Christine Lebrun-Frénay; Ruth Ann Marrie; James Overell; Fredrik Piehl; Peter Vestergaard Rasmussen; Maria José Sá; Carmen-Adella Sîrbu; Eli Skromne; Øivind Torkildsen; Vincent van Pesch; Timothy Vollmer; Magd Zakaria; Tjalf Ziemssen; Gavin Giovannoni Journal: Mult Scler Date: 2018-11-01 Impact factor: 6.312